Pharvaris (NASDAQ:PHVS) Shares Gap Down Following Insider Selling

Shares of Pharvaris N.V. (NASDAQ:PHVS) gapped down prior to trading on Friday after an insider sold shares in the company. The stock had previously closed at $30.04, but opened at $27.67. Pharvaris shares last traded at $27.5410, with a volume of 6,950 shares changing hands.

Specifically, insider Peng Lu sold 7,001 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $30.05, for a total value of $210,380.05. Following the completion of the transaction, the insider directly owned 66,083 shares of the company’s stock, valued at $1,985,794.15. This trade represents a 9.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Berndt Modig sold 2,292 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $28.60, for a total transaction of $65,551.20. Following the completion of the transaction, the chief executive officer directly owned 139,792 shares of the company’s stock, valued at $3,998,051.20. The trade was a 1.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PHVS shares. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday. Wall Street Zen lowered shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. Finally, Wedbush increased their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.73.

Pharvaris Stock Performance

The company’s fifty day moving average is $27.39 and its two-hundred day moving average is $25.80. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -8.50 and a beta of -2.58.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.15). On average, sell-side analysts anticipate that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in Pharvaris in the 4th quarter worth approximately $35,000. JPMorgan Chase & Co. increased its holdings in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Pharvaris in the 3rd quarter worth approximately $75,000. Barclays PLC acquired a new position in Pharvaris in the 4th quarter worth approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Pharvaris in the 4th quarter worth approximately $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.